Safety Study of Abatacept to Treat Rheumatoid Arthritis (A)
NCT ID: NCT01088321
Last Updated: 2016-12-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
81332 participants
OBSERVATIONAL
2005-03-31
2016-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety Study of Abatacept to Treat Rheumatoid Arthritis (B)
NCT01088360
Safety Study of Abatacept in Rheumatoid Arthritis Participants
NCT03696173
Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy
NCT00124982
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
NCT04909801
A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis
NCT00048932
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients initiating abatacept
No interventions assigned to this group
Patients initiating other biologic disease-modifying drugs
No interventions assigned to this group
Pts initiate non-biologic disease-modify anti-rheumatic drugs
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Claims indicating infusion, injection, or dispensing of abatacept, a DMARD, or a BDM
* Age 18 years or older at the time of drug initiation
* Enrollment in the health plan at least 6 continuous months leading up to the time of study drug initiation
Exclusion Criteria
* Lacking six months of continuous enrollment prior to the initiation of one of the study drugs
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IM101-045A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.